The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1601
ISSUE 1601
June 29, 2020
IV Meloxicam (Anjeso) for Pain
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
June 29, 2020 (Issue: 1601)
The FDA has approved Anjeso (Baudax Bio), an IV
formulation of the nonsteroidal anti-inflammatory
drug (NSAID) meloxicam, for once-daily treatment
of moderate to severe pain in adults. Oral meloxicam
(Mobic, and others), which is only indicated
for treatment of chronic pain associated with
osteoarthritis or rheumatoid arthritis, has been
available for 20 years. IV formulations of ketorolac,
ibuprofen (Caldolor), and acetaminophen (Ofirmev)
are also available for treatment of pain.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: IV Meloxicam (Anjeso) for Pain
Article code: 1601b
Electronic, downloadable article - $45
Article code: 1601b
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
